Moderna- 2 Vaccine Stocks That Can Double Your Money- Part1

  Moderna- 2 Vaccine Stocks That Can Double Your Money- Part1 Success stories in the stock market are not over. Coronavirus vaccine stocks skyrocketed last year. Players like Novavax (NASDAQ: NVAX) and Vaxart achieved the biggest wins, each rising more than 1,500 %. Most of the investors have bet on companies that are likely to bring vaccines to the market or have jumped with innovative technology. Three vaccines from Pfizer, Moderna (NASDAQ: MRNA) and Johnson & Johnson have entered the market these days. We no longer bet on which company will hit the finish line first. However, this does not mean that the opportunity to invest in coronavirus vaccine stocks is over. With these stocks, there are two elements that can bring big gains in the long run. There are the product revenue and development of newer vaccines, boosters to overcome the emerging coronavirus mutation. Considering all these factors, it seems highly likely that Moderna and Novavax stocks will gain investors in the coming months and years. Let's examine Moderna, one of these dynamic vaccine manufacturers, in detail.

1-Moderna

The story of this stock began with its value rising 434 % last year. The U.S. Food and Drug Administration (FDA) issued Moderna's vaccine candidate Emergency Use Authorization (EUA) in last December. Thus, the vaccine generated more than $ 199,000 in just two weeks. With the advanced acquisition agreements signed so far, a revenue of $ 18,4 billion is expected this year. This expectation is a big deal for a company that doesn't have product revenue before the vaccine launch. Stocks are not expensive right now, considering their earning potential. The stock is traded less than six times the forward-looking earnings estimates.

Moderna- 2 Vaccine Stocks That Can Double Your Money- Part1

The biotech company also looks good at examining coronavirus variants. Moderna said her vaccine protects against British and South African strains. But today's vaccines - including Moderna - are still losing some effectiveness against these variants. Therefore, the company continues its efforts to develop a more precise product. Moderna delighted the first volunteers in a study of mutation-specific enhancers. In the trial targeting the South African mutation, a new version of the vaccine that combines the vaccine and booster is being tested with high doses. The best news is that the FDA has announced that it will not request vaccine updates or extensive clinical trials for boosters from companies that have an authorized vaccine. Thus, the time to market these works will be accelerated.  

Source: The Motley Fool

 

You may also be interrested in:

 

Gold Investors Focused on FED Meeting